Hologic, Inc. (HOLX) Stake Lowered by Bank of Montreal Can

Bank of Montreal Can lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 73.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 317,601 shares of the medical equipment provider’s stock after selling 866,370 shares during the period. Bank of Montreal Can owned 0.12% of Hologic worth $13,579,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. Grove Bank & Trust raised its position in Hologic by 115.8% in the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after purchasing an additional 1,535 shares during the period. Hall Laurie J Trustee raised its position in Hologic by 10.2% in the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after purchasing an additional 225 shares during the period. MPS Loria Financial Planners LLC purchased a new position in shares of Hologic during the second quarter worth approximately $191,000. National Asset Management Inc. purchased a new position in shares of Hologic during the second quarter worth approximately $203,000. Finally, Rothschild Investment Corp IL purchased a new position in shares of Hologic during the third quarter worth approximately $236,000. 93.84% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on the stock. Cowen raised shares of Hologic to a “buy” rating and set a $52.00 target price on the stock in a research report on Wednesday, December 20th. Deutsche Bank lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a report on Friday, January 19th. Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. Stifel Nicolaus downgraded shares of Hologic from a “buy” rating to a “hold” rating and lowered their target price for the company from $45.00 to $42.00 in a research note on Friday. Finally, Needham & Company LLC restated a “buy” rating and issued a $50.00 target price on shares of Hologic in a research note on Friday, November 3rd. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Hologic has an average rating of “Buy” and an average target price of $48.36.

In other news, VP Karleen Marie Oberton sold 1,023 shares of the business’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.88% of the stock is owned by insiders.

Hologic, Inc. (NASDAQ HOLX) opened at $38.04 on Tuesday. Hologic, Inc. has a fifty-two week low of $35.33 and a fifty-two week high of $46.80. The company has a current ratio of 1.25, a quick ratio of 0.98 and a debt-to-equity ratio of 0.87. The stock has a market cap of $10,410.00, a price-to-earnings ratio of 10.04, a P/E/G ratio of 1.71 and a beta of 0.77.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The company had revenue of $791.10 million during the quarter, compared to analysts’ expectations of $785.80 million. During the same quarter in the previous year, the company earned $0.52 earnings per share. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. analysts forecast that Hologic, Inc. will post 2.25 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Hologic, Inc. (HOLX) Stake Lowered by Bank of Montreal Can” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/13/hologic-inc-holx-shares-sold-by-bank-of-montreal-can.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply